Eyepoint Pharmaceuticals topline Lugano trial results spark momentum for sustained release TKI in wet AMD

Eyepoint Pharmaceuticals topline Lugano trial results spark momentum for sustained release TKI in wet AMD
Eyepoint reports Lugano trial results

Eyepoint Pharmaceuticals revealed topline results from its Lugano trial, showing promising efficacy for sustained release tyrosine kinase inhibitors (TKIs) in the treatment of wet age-related macular degeneration (AMD).

President and CEO Jay S. Duker, M.D., discussed the findings in an interview with Retinal Physician, outlining the potential impact of long acting TKI therapies for patients. The interview highlights the ongoing advancements aimed at improving outcomes and reducing treatment burden for those with wet AMD. No additional financial details or timeline for future development were disclosed in the announcement.

Earlier this year, Eyepoint Pharmaceuticals released topline results from its pivotal Phase 3 LUGANO trial of DURAVYU for wet AMD treatment, according to company statements (link). The company also reported Q2 2026 financial results and outlined recent strategic actions in a separate disclosure (link). These updates provide context for the ongoing development of its pipeline in ophthalmology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.